



GENERAL CONFORMITY CERTIFICATE

Pursuant to 15 U.S.C. § 2063(a), Gilead Sciences, Inc. certifies that based on a reasonable testing program, the product referenced in this certificate complies with applicable regulations, rules, bans, and/or standards that are enforced by the Consumer Product Safety Commission.

Product:	Emtricitabine 200 mg/rilpivirine 25 mg/tenofovir DF 300 mg Combination Tablets, 30 count NDC 61958-1101-1
The regulation(s), rule(s), ban(s), and/or standard(s) to which this product is being certified:	16 CFR 1700.14(a)(10) 16 CFR 1700.15
Manufacturer or importer certifying compliance:	Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA Phone: 1-800-GILEAD-5
Individual maintaining test records upon which this certification is based:	Director of Global Operations Quality Assurance Gilead Sciences, Inc. 333 Lakeside Drive Foster City, CA 94404 USA Phone: 1-800-GILEAD-5 Email address: globalqa@gilead.com
Date and place where this product was manufactured:	Gilead products are coded with a unique lot number. The lot number can be used to identify the date and place of packaging by calling 1-800-GILEAD-5, prompt number 2, then prompt number 8.
Date and place where this product was tested for compliance with the regulation(s), rule(s), ban(s) and/or standard(s) cited above and test report(s) on which certification is based:	2801 Junipero Avenue #206 Signal Hill, CA 90755 and 2606 East 3300 South Salt Lake City, UT 84109 Test Report # C100-572 dated January 8, 2010 Test Report # U200-532 dated December 2, 2010 Test Report #U200-632 dated February 3, 2012 The specific test report applicable to this product depends on the configuration used.
Third party laboratory that conducted testing upon which this certification is based:	Child Related Research, Inc. 2605 East 3300 South Salt Lake City, Utah 84109 Phone: (801) 467-9440

Effective date: 29 June 2012